Chinese expert consensus on wound repair of venous leg ulcers (2025 edition)

Mil Med Res. 2026;13(1):100058. doi: 10.1016/j.mmr.2026.100058. Epub 2026 Jul 30.ABSTRACTVenous leg ulcers (VLUs) result from a multifactorial interplay of etiological factors, posing significant challenges in clinical management. Effective treatment requires a comprehensive assessment to identify t

P Pi-Hong Zhang

LR11/SorLA and its role in cardiovascular disease

Int J Cardiol Heart Vasc. 2026 Jul 31;66:101982. doi: 10.1016/j.ijcha.2026.101982. eCollection 2026 Oct.ABSTRACTCardiovascular diseases account for the highest morbidity worldwide. LR11 (also called SorLA), an LDL receptor family member characterized as a sorting receptor, was initially identified i

M Meander Kloosterman

Semaglutide attenuates a proteomics-based dementia risk signature in older adults with overweight or obesity and cardiovascular disease without diabetes: A post hoc analysis of the SELECT phase 3 trial

Alzheimers Dement (Amst). 2026 Aug 8;18(3):e70432. doi: 10.1002/dad2.70432. eCollection 2026 Jul-Sep.ABSTRACTINTRODUCTION: Plasma proteomics detect multi-pathway biological changes preceding dementia onset. The Dementia SomaSignal Test (dSST) is a validated 25-protein score predicting 5- and 20-year

M Martí Jiménez-Mausbach

Primary Leiomyosarcoma of the Superior Vena Cava: A Rare Case Report

Iran J Med Sci. 2026 Jul 1;51(7):523-527. doi: 10.30476/ijms.2026.109892.4532. eCollection 2026 Jul.ABSTRACTLeiomyosarcoma of the superior vena cava (SVC) is an exceptionally rare vascular tumor. Fewer than 20 cases were reported worldwide. Because of the nonspecific nature of the presenting symptom

A Andrey Ryabov

Baseline, repeated-measure burden, and two-time-point patterns of the triglyceride-glucose index-visceral lipid ratio (TyG-VLR) and incident cardiovascular disease in cardiovascular-kidney-metabolic (CKM) syndrome stages 0-3: a longitudinal China Health and Retirement Longitudinal Study (CHARLS) analysis

Cardiovasc Diabetol. 2026 Jul 25;25(1):221. doi: 10.1186/s12933-026-03302-0.ABSTRACTBACKGROUND: Cardiovascular-kidney-metabolic (CKM) syndrome stages 0-3 define a population without overt clinical cardiovascular disease (CVD) but with accumulating metabolic, adiposity, lipid, and kidney-related risk

A Ao-Men Lu